Sorrento Therapeutics Inc (SRNE)

[dia76ca]

Merck claims that their anti-viral pill is about 50% effective in preventing hospitalizations and deaths in Covid patients. How might COVIDROPS compare? We have no COVIDROPS published data but competitor Mabs are about 80% effective and Sorrento has suggested that COVIDROPS might improve on that! However competitor Mabs are very expensive and require several hours for infusion in overcrowded infusion centers. COVIDROPS could be administered in a few minutes in the doctors office, the pharmacy or even at home.

What are COVIDROPS advantages compared to competitor Mabs?
1. COVIDROPS efficacy may significantly exceed 80%.
2. They only require 1/50th of the dosage of competitor Mabs. This smaller dosage reduces cost and potential negative adverse events.
3. They can be produced using the the C1 technology. This allows for production runs producing 10 times the quantity of the competitors production adding even more cost savings!
4. They do not require costly hospital or infusion center time.

Just as COVISTIX was first approved in Mexico and will likely be approved next in Brazil, Canada, the UK and Europe, we should expect the same for COVIDROPS. Dr.Ji has stated that they plan to speed up trials in the US by working directly with State governments.
I look forward to international marketing partnerships and worldwide multi-Billion sales!